Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2
Episode 104, Dec 15, 2023, 11:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.
Looking for more sleep disorders discussion? Check out the NeurologyLive® narcolepsy clinical focus page.
Episode Breakdown:
In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.
Looking for more sleep disorders discussion? Check out the NeurologyLive® narcolepsy clinical focus page.
Episode Breakdown:
- 1:10 – Overview of post-hoc analysis of REST-ON
- 3:15 – Differences in type 1 and 2 narcolepsy
- 5:50 – Neurology News Minute
- 8:15 – Expanding treatment profile of once-nightly sodium oxybate
- 10:55 – Lingering unmet needs of patients with narcolepsy
- 11:20 – Realistic timeline of gene therapies for epilepsy
- 14:00 – Future of narcolepsy research, drug development trials
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis
ALS Candidate PrimeC Meets Primary Safety and Secondary End Points in Phase 2b PARADIGM Study
FDA Clears NeuroOne’s OneRF Ablation System for Neurosurgerical Procedures
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.